Knight Therapeutics (OTCMKTS:KHTRF) Shares Cross Below Fifty Day Moving Average – Time to Sell?

Knight Therapeutics Inc. (OTCMKTS:KHTRF)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $4.25 and traded as low as $4.10. Knight Therapeutics shares last traded at $4.10, with a volume of 2,227 shares traded.

Knight Therapeutics Stock Down 2.1 %

The business has a 50 day moving average of $4.25 and a 200-day moving average of $4.21.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.